Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.63 |
| ▸ | EGFR | P00533 | 12/20 | 0.56 |
| ▸ | CLK1 | P49759 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | KIF5B | P33176 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945652 | 0.88 | KDR (0.68) | KDREGFRCLK1ABCG2RET | |
| SCHEMBL11931697 | 0.84 | KDR (0.54) | KDREGFRCLK1ABCG2RET | |
| SCHEMBL11931696 | 0.81 | KDR (0.78) | KDREGFRRETKIF5B | |
| SCHEMBL12456408 | 0.79 | KDR (0.52) | KDREGFRRETKIF5B | |
| SCHEMBL12456411 | 0.79 | CSF1R (0.55) | KDREGFRRETKIF5B | |
| SCHEMBL11931701 | 0.76 | KDR (0.69) | KDRRETKIF5B | |
| SCHEMBL6162952 | 0.74 | KDR (0.70) | KDREGFRABCG2 | |
| SCHEMBL6162829 | 0.74 | KDR (0.70) | KDREGFRABCG2 | |
| SCHEMBL6662871 | 0.74 | KDR (0.77) | KDREGFRRET | |
| SCHEMBL5565137 | 0.73 | EGFR (1.00) | KDREGFRCLK1ABCG2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497372-B2 | Use of substituted quinazoline compounds in treating age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-07-30 | — | — | US | disclosed |
| US-20120238572-A1 | USE OF SUBSTITUTED QUINAZOLINE COMPOUNDS IN TREATING ANGIOGENESIS-RELATED DISEASES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED | 2012-09-20 | — | — | US | disclosed |
| US-8212033-B2 | Use of substituted quinazoline compounds in treating angiogenesis-related diseases | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2012-07-03 | — | — | US | disclosed |
| US-20110015213-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERRISES LIMITED | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238572-A1 | USE OF SUBSTITUTED QUINAZOLINE COMPOUNDS IN TREATING ANGIOGENESIS-RELATED DISEASES | FLT4, FLT1, CXCR4 | KDR 6/4885EGFR 768/4885CLK1 1216/4885 |
| US-20110015213-A1 | QUINAZOLINE DERIVATIVES | FLT4, FLT1, ARG1 | KDR 4/4885EGFR 1127/4885CLK1 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.